

Claus Garbe

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1691756/claus-garbe-publications-by-year.pdf>

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

746 papers	50,946 citations	99 h-index	209 g-index
879 ext. papers	59,865 ext. citations	4.7 avg, IF	7.2 L-index

#	Paper	IF	Citations
746	Diagnostic and prognostic classification of atypical spitzoid tumours based on histology and genomic aberrations: A prospective cohort study with long-term follow-up.. <i>European Journal of Cancer</i> , 2022 , 163, 200-210	7.5	0
745	TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 , 1	4.9	0
744	Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. <i>European Journal of Cancer</i> , 2021 , 159, 98-104	7.5	2
743	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. <i>European Journal of Cancer</i> , 2021 , 162, 22-33	7.5	2
742	30 years German Dermatologic Cooperative Oncology Group (DeCOG). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 1682-1697	1.2	
741	Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition. <i>Molecular and Cellular Proteomics</i> , 2021 , 20, 100163	7.6	2
740	30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 1682-1697	1.2	
739	Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma. <i>Frontiers in Oncology</i> , 2021 , 11, 643156	5.3	3
738	A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences. <i>British Journal of Dermatology</i> , 2021 , 185, 101-109	4	4
737	Neoadjuvant and adjuvant end-points in health technology assessment in oncology. <i>European Journal of Cancer</i> , 2021 , 147, 40-50	7.5	1
736	PET/CT in malignant melanoma: a two-tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 852-862	1.2	0
735	TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9524-9524	2.2	
734	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9507-9507	2.2	6
733	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 655-664	21.7	9
732	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 643-654	21.7	58
731	5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021 ,	12.9	10
730	Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. <i>European Journal of Cancer</i> , 2021 , 152, 18-25	7.5	8

729	Not all melanomas are created equal: a review and call for more research into nodular melanoma. <i>British Journal of Dermatology</i> , 2021 , 185, 700-710	4	2
728	Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. <i>European Journal of Cancer</i> , 2021 , 143, 11-18	7.5	4
727	Improved protection of outdoor workers from solar ultraviolet radiation: position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1278-1284	4.6	8
726	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1119-1132	4.6	3
725	Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1089-1099	7.4	1
724	Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. <i>Targeted Oncology</i> , 2021 , 16, 197-205	5	5
723	Online consensus conferences for the development and update of clinical practice guidelines: A survey among participants of the German S3 guideline on actinic keratosis and cutaneous squamous cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 608-610	1.2	2
722	Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas. <i>Cancers</i> , 2021 , 13,	6.6	3
721	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021 , 152, 116-128	7.5	2
720	The impact of the COVID-19 pandemic on diagnostic delay of skin cancer: a call to restart screening activities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e836-e837	4.6	4
719	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2149-2153	4.6	3
718	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1949-1956	4.6	3
717	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis: A Systematic Review and Network Meta-analysis. <i>JAMA Dermatology</i> , 2021 , 157, 1066-1077	5.1	4
716	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. <i>Cancers</i> , 2021 , 13,	6.6	1
715	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	14
714	Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?. <i>Cancers</i> , 2020 , 12,	6.6	4
713	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020 , 395, 1558-1568	4.0	100
712	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , 2020 , 134, 9-18	7.5	4

711	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2543-2551	2.2	13
710	Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study. <i>OncoTargets and Therapy</i> , 2020 , 13, 5017-5032	4.4	4
709	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020 , 8,		19
708	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020 , 130, 126-138	7.5	39
707	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 275-294	1.2	25
706	Influence of F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2313-2321	8.8	1
705	MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. <i>Cancers</i> , 2020 , 12,	6.6	27
704	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020 , 128, 60-82	7.5	60
703	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020 , 128, 83-102	7.5	76
702	Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2021-2025	4.6	6
701	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. <i>European Journal of Cancer</i> , 2020 , 126, 141-158	7.5	63
700	Pitfalls in the characterization of circulating and tissue-resident human T cells. <i>Journal of Leukocyte Biology</i> , 2020 , 107, 1097-1105	6.5	7
699	Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. <i>European Journal of Cancer</i> , 2020 , 131, 100-103	7.5	3
698	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 400-413	1.2	19
697	Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020 , 12,	6.6	5
696	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients 2020 , 8,		27
695	Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. <i>Australasian Journal of Dermatology</i> , 2020 , 61, e310-e318	1.3	4
694	433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial 2020 , 8, A459-A459		1

693	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10012-10012	2.2	10
692	Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase. <i>Acta Dermato-Venereologica</i> , 2020 , 100, adv00174	2.2	
691	Melanoma in Children and Teenagers 2020 , 969-982		
690	Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer. <i>Acta Dermato-Venereologica</i> , 2020 , 100, adv00328	2.2	2
689	Mucosal Melanoma 2020 , 953-968		
688	Acral Lentiginous Melanoma 2020 , 897-924		
687	Epidemiology of Skin Cancer: Update 2019. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1268, 123-139	3.6	58
686	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa140	0.9	3
685	Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 956-966	4.6	9
684	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive F-FDG-PET. <i>Theranostics</i> , 2020 , 10, 925-937	12.1	26
683	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020 , 126, 33-44	7.5	74
682	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. <i>European Journal of Cancer</i> , 2020 , 126, 159-177	7.5	81
681	Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. <i>European Journal of Cancer</i> , 2020 , 125, 38-45	7.5	15
680	Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 136-139	1.2	3
679	Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 932-941	4.6	17
678	Late recurrence of melanoma after 10 years - Is the course of the disease different from early recurrences?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 977-983	4.6	1
677	Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. <i>European Journal of Cancer</i> , 2020 , 140, 154-157	7.5	1
676	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients 2020 , 8,		19

675	Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. <i>American Journal of Pathology</i> , 2020 , 190, 2155-2164	5.8	2
674	Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknesses. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 682-690	1.2	1
673	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1944-1956	4.6	46
672	Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma-Old Myth or New Logos?. <i>Cancers</i> , 2020 , 12,	6.6	16
671	Toxic epidermal necrolysis in a melanoma patient under targeted therapy with encorafenib and binimetinib. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 1159-1161	1.2	
670	A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
669	Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition. <i>Cell Death and Disease</i> , 2020 , 11, 581	9.8	6
668	Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020 , 12,	6.6	12
667	Is there a link between very early changes of primary and secondary lymphoid organs in F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? 2020 , 8,		7
666	The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2183-2197	4.6	10
665	The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019 2020 , 8,		1
664	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2020 , 18, 346	8.5	2
663	Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion. <i>Cancers</i> , 2020 , 12,	6.6	8
662	Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. <i>Cancers</i> , 2020 , 12,	6.6	12
661	Diagnostic Performance of a Support Vector Machine for Dermatofluoroscopic Melanoma Recognition: The Results of the Retrospective Clinical Study on 214 Pigmented Skin Lesions. <i>Diagnostics</i> , 2019 , 9,	3.8	4
660	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 119, 168-178	7.5	32
659	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1547-1559	7.4	23
658	Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3000-3008	2.2	72

657	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019 , 109, 61-69	7.5	18
656	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 207-215	7.5	26
655	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 626-636	59.2	489
654	S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019 , 17, 663-668	1.2	10
653	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). <i>European Journal of Cancer</i> , 2019 , 114, 117-127	7.5	64
652	Meningeal enhancement depicted by magnetic resonance imaging in tumor patients: neoplastic meningitis or therapy-related enhancement?. <i>Neuroradiology</i> , 2019 , 61, 775-782	3.2	4
651	Kein Überlebensvorteil beim Sentinel-Lymphknoten-positiven Melanom mit sofortiger kompletter Lymphadenektomie - eine Übersicht. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019 , 17, 7-14	1.2	
650	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with -mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 3239-3246	12.9	23
649	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1314-1322	9.7	17
648	Modifiable Risk-factors for Keratinocyte Cancers in Australia: A Case-control Study. <i>Acta Dermato-Venereologica</i> , 2019 , 99, 404-411	2.2	1
647	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1299-1307.e7	4.5	4
646	Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 63-70	4.6	7
645	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. <i>PLoS ONE</i> , 2019 , 14, e0221301	3.7	9
644	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019 , 119, 97-106	7.5	27
643	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study 2019 , 7, 180		74
642	Acral Lentiginous Melanoma 2019 , 1-28		1
641	Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. <i>British Journal of Cancer</i> , 2019 , 121, 417-420	8.7	17
640	S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019 , 17, 663-668	1.2	4

639	Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019 , 118, 10-34	7.5	152
638	Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). <i>Annals of Oncology</i> , 2019 , 30, v903-v904	10.3	3
637	Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial. <i>Annals of Oncology</i> , 2019 , 30, v906-v907	10.3	7
636	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019 , 121, 144-153	7.5	19
635	Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set. <i>Trials</i> , 2019 , 20, 589	2.8	1
634	Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. <i>European Journal of Cancer</i> , 2019 , 123, 83-91	7.5	8
633	Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33 Suppl 8, 44-51	4.6	17
632	Targeting tumor-resident mast cells for effective anti-melanoma immune responses. <i>JCI Insight</i> , 2019 , 4,	9.9	16
631	Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600E mutant unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9507-9517	5.2	4
630	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9512-9512	2.2	11
629	Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9518-9518	2.2	1
628	Melanoma in Children and Teenagers 2019 , 1-14		
627	Mucosal Melanoma 2019 , 1-17		1
626	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 765-772	7.4	23
625	Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies 2019 , 7, 343		24
624	Local interventions for actinic keratosis in organ transplant recipients: a systematic review. <i>British Journal of Dermatology</i> , 2019 , 180, 43-50	4	15
623	An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019 , 107, 175-185	7.5	7
622	BRAF mutation testing in melanoma: results from a German observational multicenter study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 71-78	5.1	1

621	Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. <i>Immunotherapy</i> , 2019 , 11, 297-309	3.8	16
620	Time trends in incidence and mortality of cutaneous melanoma in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1272-1280	4.6	29
619	Lack of survival benefit in sentinel lymph node-positive melanoma with immediate complete lymphadenectomy - a review. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019 , 17, 7-13	1.2	5
618	The iris signal: blue periphery, tan collaret and freckles pattern - strong indicators for epidermal skin cancer in South-Eastern Europe. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1662-1667	4.6	2
617	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF mutation-positive melanoma. <i>British Journal of Cancer</i> , 2018 , 118, 777-784	8.7	14
616	Pediatric patients with cutaneous melanoma: A European study. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26974	3	17
615	How to use neoadjuvant medical treatment to maximize surgery in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 121-130	3.5	7
614	The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival. <i>European Journal of Cancer</i> , 2018 , 91, 1-10	7.5	8
613	Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells. <i>Biology Open</i> , 2018 , 7,	2.2	5
612	Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions. <i>British Journal of Dermatology</i> , 2018 , 179, 478-485	4	12
611	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 603-615	21.7	451
610	Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. <i>British Journal of Dermatology</i> , 2018 , 178, 443-451	4	51
609	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	49
608	Safety of shortened infusion times for combined ipilimumab and nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 135-140	7.4	2
607	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 95-101	8.8	40
606	Patient acceptance and trust in automated computer-assisted diagnosis of melanoma with dermatofluoroscopy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018 , 16, 854-859	1.2	7
605	Patientenakzeptanz und -vertrauen in die automatisierte, computergestützte Diagnostik des Melanoms mithilfe der Dermatofluoroskopie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018 , 16, 854-860	1.2	5
604	Vemurafenib. <i>Recent Results in Cancer Research</i> , 2018 , 211, 77-89	1.5	26

603	Quality assurance in melanoma care: The EU-MELACARE study. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1773-1778	3.6	1
602	Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. <i>Molecular Cancer</i> , 2018 , 17, 59	42.1	41
601	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018 , 16,	8.5	1
600	YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT. <i>Molecular Cancer Research</i> , 2018 , 16, 1149-1160	6.6	26
599	Fear of cancer progression in patients with stage IA malignant melanoma. <i>European Journal of Cancer Care</i> , 2018 , 27, e12901	2.4	9
598	Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9501-9501	2.2	12
597	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9504-9504	2.2	19
596	Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9522-9522	2.2	21
595	Adverse events of special interest in the phase 3 COLUMBUS study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9567-9567	2.2	2
594	Next-generation-sequencing of advanced melanoma: Which genetic alterations have an impact on systemic therapy response?. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21557-e21557	2.2	
593	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018 , 91, 168-170	7.5	23
592	Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma. <i>European Radiology</i> , 2018 , 28, 1456-1464	8	5
591	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1658-1667	2.2	357
590	Effects of Molecular Heterogeneity on Survival of Patients With -Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-18	3.6	2
589	6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells. <i>Cellular Physiology and Biochemistry</i> , 2018 , 51, 543-556	3.9	9
588	Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. <i>Lancet Oncology, The</i> , 2018 , 19, e720-e725	21.7	23
587	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. <i>European Journal of Cancer</i> , 2018 , 104, 201-209	7.5	22
586	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018 , 104, 137-144	7.5	63

585	Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. <i>Annals of Oncology</i> , 2018 , 29, 2208-2213	10.3	93
584	Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1845-1851	7.4	16
583	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1315-1327	21.7	291
582	Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs. <i>Cell Death and Disease</i> , 2018 , 9, 930	9.8	5
581	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , 2018 , 119, 339-346	8.7	55
580	GSTP1 does not modify MC1R effects on melanoma risk. <i>Experimental Dermatology</i> , 2017 , 26, 730-733	4	9
579	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. <i>European Journal of Cancer</i> , 2017 , 75, 313-322	7.5	25
578	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 435-445	21.7	240
577	MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. <i>European Journal of Cancer</i> , 2017 , 73, 93-101	7.5	54
576	The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. <i>European Journal of Cancer</i> , 2017 , 73, 85-92	7.5	67
575	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017 , 73, 61-70	7.5	59
574	Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1. <i>Experimental Dermatology</i> , 2017 , 26, 598-606	4	11
573	Non-melanoma skin cancer: new and future synthetic drug treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 689-699	4	15
572	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , 2017 , 79, 176-184	7.5	23
571	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017 , 28, 1631-1639	10.3	361
570	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer</i> , 2017 , 17, 332	4.8	196
569	S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017 , 15, e1-e41	1.2	19
568	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017 , 82, 45-55	7.5	114

567	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 611-622	21.7	306
566	Impact of F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1312-1318	8.8	19
565	Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. <i>Annals of Oncology</i> , 2017 , 28, 634-641	10.3	124
564	Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 703-708	4.9	4
563	Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 441-449	7.4	22
562	Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. <i>Journal of Immunology</i> , 2017 , 198, 927-936	5.3	27
561	Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1860-1867	4.3	78
560	The need for psycho-oncological support for melanoma patients: Central role of patients' self-evaluation. <i>Medicine (United States)</i> , 2017 , 96, e7987	1.8	7
559	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017 , 67, 472-492	220.7	1044
558	Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). <i>Klinische Padiatrie</i> , 2017 , 229, 322-328	0.9	13
557	Genomics of Immunotherapy-Associated Hyperprogressors-Letter. <i>Clinical Cancer Research</i> , 2017 , 23, 6374-6375	12.9	10
556	Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. <i>Annals of Oncology</i> , 2017 , 28, v442	10.3	2
555	Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. <i>Annals of Oncology</i> , 2017 , 28, v429-v430	10.3	23
554	Reply to 'Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma'. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1537	4	
553	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. <i>European Journal of Cancer</i> , 2017 , 83, 247-257	7.5	181
552	Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017 , 18, 517-532	10.5	32
551	Immunotherapy in managing metastatic melanoma: which treatment when?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1523-1538	5.4	7
550	Pembrolizumab-induced hepatitis: diagnosis and treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017 , 15, 933-935	1.2	3

549	Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2570-2577	4.3	19
548	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017 , 23, 6203-6214	12.9	22
547	Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2309-2315	4.3	67
546	Adjuvant interferon- γ for the treatment of high-risk melanoma: An individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017 , 82, 171-183	7.5	114
545	Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. <i>European Journal of Cancer</i> , 2017 , 81, 203-205	7.5	30
544	Imaging characteristics of cardiac metastases in patients with malignant melanoma. <i>Cancer Imaging</i> , 2017 , 17, 19	5.6	8
543	Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen. <i>European Radiology</i> , 2017 , 27, 2538-2545	8	6
542	Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 533-540	4.9	35
541	Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase. <i>Oncotarget</i> , 2017 , 8, 35761-35775	3.3	13
540	Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9509-9509	2.2	22
539	The demand for psycho-oncological support in 820 melanoma patients: What are the determinants for the development of distress?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9514-9514	2.2	0
538	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9524-9524	2.2	14
537	Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma. <i>PLoS ONE</i> , 2017 , 12, e0188602	3.7	4
536	Melanoma of the Skin 2017 , 563-586		58
535	Fear of progression in patients with low-risk malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21615-e21615	2.2	
534	An open-label, uncontrolled, single arm phase II trial of the PI3K inhibitor buparlisib in patients with melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS9595-TPS9595	2.2	1
533	Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der Immunhistologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016 , 14, 910-6	1.2	8
532	Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone. <i>Annals of Oncology</i> , 2016 , 27, vi379	10.3	9

531	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <i>Journal of Translational Medicine</i> , 2016 , 14, 65	8.5	8
530	Preferences of German melanoma patients for interferon (IFN) β -2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy. <i>Medicine (United States)</i> , 2016 , 95, e5375	1.8	8
529	Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study). <i>BMJ Open</i> , 2016 , 6, e012730	3	8
528	High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera. <i>Proteomics</i> , 2016 , 16, 1570-80	4.8	47
527	Phenotypic characterization and prognostic impact of circulating $\gamma\delta$ and $\alpha\beta$ T-cells in metastatic malignant melanoma. <i>International Journal of Cancer</i> , 2016 , 138, 698-704	7.5	22
526	Adjuvant treatment with pegylated interferon β -2a versus low-dose interferon β -2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. <i>Annals of Oncology</i> , 2016 , 27, 1625-32	10.3	15
525	PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. <i>Clinical Cancer Research</i> , 2016 , 22, 5818-5828	12.9	53
524	A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. <i>EBioMedicine</i> , 2016 , 8, 132-149	8.8	30
523	CT imaging of bone and bone marrow infiltration in malignant melanoma--Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. <i>European Journal of Radiology</i> , 2016 , 85, 732-8	4.7	26
522	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 2908-18	12.9	372
521	Intralesional immunotherapy as a strategy to treat melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 619-26	5.4	14
520	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016 , 53, 125-34	7.5	115
519	Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 482-8	8.8	27
518	Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study. <i>European Radiology</i> , 2016 , 26, 1826-34	8	8
517	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9526-9526	2.2	2
516	Evaluation of photosensitivity in dabrafenib treated metastatic melanoma patients: Results from a phase IIa study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21077-e21077	2.2	1
515	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. <i>Oncotarget</i> , 2016 , 7, 36130-36137	3.3	8
514	Acquired resistance mechanisms to immunotherapy. <i>Annals of Translational Medicine</i> , 2016 , 4, 547	3.2	1

513 Kutane Nebenwirkungen neuer Krebsmedikamente **2016**, 305-312

512 Melanozytäre Nävi und Melanom **2016**, 609-668

511 Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP).. *Journal of Clinical Oncology*, **2016**, 34, 9558-9558 2.2

510 Factors influencing BRAFV600 mutation testing quality in melanoma: Results from a large, non-interventional, multicenter study in Germany.. *Journal of Clinical Oncology*, **2016**, 34, e23142-e23142^{2,2}

509 Proportions of blood-borne Vβ1+ and Vβ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. *European Journal of Cancer*, **2016**, 64, 116-26 7.5 36

508 Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. *European Journal of Cancer*, **2016**, 63, 201-17 7.5 265

507 The many unanswered questions related to the German skin cancer screening programme. *European Journal of Cancer*, **2016**, 64, 83-8 7.5 20

506 Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, controlled 12-month study. *British Journal of Dermatology*, **2016**, 174, 505-13 4 26

505 UVA-Irradiation Induces Melanoma Invasion via the Enhanced Warburg Effect. *Journal of Investigative Dermatology*, **2016**, 136, 1866-1875 4.3 19

504 Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. *Clinical Cancer Research*, **2016**, 22, 5487-5496 12.9 373

503 The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma. *Expert Review of Anticancer Therapy*, **2016**, 16, 705-15 3.5 6

502 Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. *European Journal of Cancer*, **2016**, 60, 210-25 7.5 391

501 Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. *European Journal of Cancer*, **2016**, 60, 190-209 7.5 412

500 Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. *Lancet Oncology*, **2016**, 17, 757-767 21.7 406

499 Das kutane Plattenepithelkarzinom | Frühzeitige Diagnose und Therapie sind entscheidend. *Kliniker*, **2016**, 45, 184-189 0

498 Das Basalzellkarzinom | Diagnostik und Management. *Kliniker*, **2016**, 45, 190-195 0

497 Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. *Clinical Cancer Research*, **2016**, 22, 4848-4858 12.9 108

496 Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry. *JDDG - Journal of the German Society of Dermatology*, **2016**, 14, 910-5 1.2 4

495	Früherkennung von Hautkrebs und Screeninguntersuchungen. <i>Onkologe</i> , 2016 , 22, 537-549	0.1	
494	High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 2444-2452	4.3	17
493	Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 1248-60	21.7	590
492	Development of a microsimulation of melanoma mortality for evaluating the effectiveness of population-based skin cancer screening. <i>Medical Decision Making</i> , 2015 , 35, 243-54	2.5	7
491	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015 , 51, 1989-2007	7.5	292
490	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015 , 2, 671-80	8.8	67
489	Immunotherapy: Combined immunotherapy--a new standard in metastatic melanoma?. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 439-40	19.4	8
488	Targeted Therapies for Melanoma 2015 , 1529-1541		
487	Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015 , 51, 2604-8	7.5	72
486	443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. <i>European Journal of Cancer</i> , 2015 , 51, 861-8	7.5	37
485	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 833-40	7.5	60
484	Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4073-80	3.1	21
483	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15003	51.1	283
482	Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1191-6	2.2	334
481	Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment. <i>International Journal of Dermatology</i> , 2015 , 54, 419-23	1.7	
480	Decreased Plasma Ascorbate Levels in Stage IV Melanoma Patients 2015 , 01, e2-e6		8
479	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015 , 51, 2396-403	7.5	170
478	The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma. <i>OncImmunology</i> , 2015 , 4, e955683	7.2	4

477	Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. <i>British Journal of Dermatology</i> , 2015 , 172, 926-32	4	9
476	Melanozytäre Nävi und Melanom 2015 , 1-87		
475	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015 , 13, 351	8.5	47
474	Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. <i>International Journal of Cancer</i> , 2015 , 137, 2607-17	7.5	22
473	Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. <i>PLoS ONE</i> , 2015 , 10, e0118564	3.7	155
472	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. <i>PLoS ONE</i> , 2015 , 10, e0139438	3.7	23
471	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	4.0	926
470	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 1075-82	7.4	12
469	Melanom der Haut [Fakten und Irrtümer. <i>CME (Berlin, Germany)</i> , 2015 , 12, 47-55	0	0
468	Partial Histological Tumor Regression in Primary Melanoma as Protective Factor for Lymph Node Micrometastasis. <i>JAMA Dermatology</i> , 2015 , 151, 1291-1292	5.1	4
467	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology, The</i> , 2015 , 16, 15-7	21.7	9
466	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1906-1913	2.2	2
465	Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9006-9006	2.2	31
464	Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9021-9021	2.2	3
463	Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA9002-LBA9002	2.2	7
462	In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 671-3	4.5	22
461	The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines. <i>Journal of Cellular and Molecular Medicine</i> , 2014 , 18, 530-41	5.6	26
460	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1867-76	59.2	1403

459	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1877-88	59.2	1195
458	Adjuvante Strategien bei Hochrisikomelanomen. <i>Onkologe</i> , 2014 , 20, 555-567	0.1	2
457	Raman spectroscopy as an analytical tool for melanoma research. <i>Clinical and Experimental Dermatology</i> , 2014 , 39, 636-45	1.8	24
456	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , 2014 , 15, 323-32	21.7	753
455	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , 2014 , 15, 436-44	21.7	206
454	Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. <i>Melanoma Management</i> , 2014 , 1, 115-125	2.1	1
453	Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. <i>PLoS ONE</i> , 2014 , 9, e86194	3.7	35
452	BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. <i>PLoS ONE</i> , 2014 , 9, e89218	3.7	16
451	Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?. <i>OncoImmunology</i> , 2014 , 3, e27845	7.2	16
450	Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. <i>Clinical Cancer Research</i> , 2014 , 20, 1601-9	12.9	192
449	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. <i>Annals of Oncology</i> , 2014 , 25, 700-706	10.3	40
448	Vemurafenib. <i>Recent Results in Cancer Research</i> , 2014 , 201, 215-25	1.5	23
447	Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. <i>PLoS Medicine</i> , 2014 , 11, e1001604	11.6	37
446	Epigenetic impacts of ascorbate on human metastatic melanoma cells. <i>Frontiers in Oncology</i> , 2014 , 4, 227	5.3	31
445	Epidemiology of skin cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 810, 120-40	3.6	291
444	Limited efficacy of intratumoral IL-2 applied to large melanoma metastases. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 1231-2	7.4	4
443	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. <i>Cancer Immunology Research</i> , 2014 , 2, 668-78	12.5	66
442	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , 2014 , 120, 2016-24	6.4	15

441	Processing of laminin β chains generates peptides involved in wound healing and host defense. <i>Journal of Innate Immunity</i> , 2014 , 6, 467-84	6.9	35
440	Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naïve patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'. <i>Melanoma Research</i> , 2014 , 24, 237-43	3.3	28
439	Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. <i>Melanoma Research</i> , 2014 , 24, 512-6	3.3	30
438	Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. <i>Journal of Immunotherapy</i> , 2014 , 37, 374-81	5	19
437	Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma. <i>Clinical Cancer Research</i> , 2014 , 20, 4390-9	12.9	30
436	New diagnostic method for lesions with transepidermal melanocytic migration. <i>JAMA Dermatology</i> , 2014 , 150, 654-6	5.1	2
435	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9011-9011	2.2	26
434	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9013-9013	2.2	11
433	Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9031-9031	2.2	2
432	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9041-9041	2.2	2
431	Predictive importance of ulceration on the efficacy of adjuvant interferon- α (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9067-9067	2.2	9
430	A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma: NICCI.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9116-TPS9116	2.2	1
429	Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. <i>PLoS ONE</i> , 2014 , 9, e112535	3.7	17
428	Quantitative assessment of melanoma spread in sentinel and non-sentinel lymph nodes and survival.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9082-9082	2.2	
427	Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9061-9061	2.2	
426	NY-ESO-1 specific CD4+ Thelper1 cells for immunotherapy of cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3071-3071	2.2	
425	Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9062-9062	2.2	
424	RAGE ligand S100A8/A9 as a novel prognostic biomarker for high-risk melanoma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9070-9070	2.2	

423	Senescence induction in human melanoma by the combined action of type II interferon and tumor necrosis factor.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22213-e22213	2.2	
422	Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIb (AJCC 2002)Decog-trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9071-9071	2.2	1
421	The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9113-TPS9113	2.2	
420	Die neue S3-Leitlinie MelanomBest Practice Onkologie, 2013 , 8, 40-48	0	0
419	Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 616-22	2.2	607
418	Proliferative activity, chromosomal aberrations, and tumor-specific mutations in the differential diagnosis between blue nevi and melanoma. <i>American Journal of Pathology</i> , 2013 , 182, 640-5	5.8	32
417	The role of radiotherapy in the overall treatment of melanoma. <i>Clinics in Dermatology</i> , 2013 , 31, 282-9	3	9
416	Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. <i>European Journal of Cancer</i> , 2013 , 49, 166-74	7.5	33
415	New landscape in the treatment of melanoma: a 2012 update. <i>Oncologie</i> , 2013 , 15, 71-77	1	1
414	Protein kinase inhibitors in melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 2195-201	4	7
413	Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 846-53	1.2	3
412	Effective combination of photodynamic therapy and imiquimod 5% cream in the treatment of actinic keratoses: three cases. <i>BioMed Research International</i> , 2013 , 2013, 102698	3	7
411	S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. <i>Melanoma Research</i> , 2013 , 23, 396-401	3.3	22
410	Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naïve patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1211-8	2.2	78
409	Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis. <i>JAMA Dermatology</i> , 2013 , 149, 642-4	5.1	6
408	Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. <i>Science Signaling</i> , 2013 , 6, ra7	8.8	96
407	Brief S2k guidelines--Basal cell carcinoma of the skin. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11 Suppl 3, 10-5, 11-6	1.2	21
406	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. <i>Cancer Medicine</i> , 2013 , 2, 76-85	4.8	102

405	Antimicrotubule Agents 2013 , 208-214		1
404	Malignes Melanom S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms JDDG - <i>Journal of the German Society of Dermatology</i> , 2013 , 11, 1-126	1.2	3
403	Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11 Suppl 6, 1-116, 1-126	1.2	79
402	Das Wichtigste für die Praxis. <i>Hautnah Dermatologie</i> , 2013 , 29, 294-301	0	
401	Brief S2k guidelines--Dermatofibrosarcoma protuberans. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11 Suppl 3, 16-8, 17-9	1.2	8
400	S2k Kurzleitlinie [Plattenepithelkarzinom der Haut. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 39-47	1.2	12
399	S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 563-602	1.2	29
398	Brief S2k guidelines--Cutaneous squamous cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11 Suppl 3, 37-45, 39-47	1.2	33
397	Molekulargenetische Klassifikation schwieriger melanozytärer Tumoren. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 12-19	1.2	1
396	Molecular genetic classification of difficult melanocytic tumors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11 Suppl 4, 11-8	1.2	6
395	S2k Kurzleitlinie [Basalzellkarzinom der Haut. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 11-16	1.2	9
394	Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. <i>PLoS ONE</i> , 2013 , 8, e63137	3.7	18
393	Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour. <i>PLoS ONE</i> , 2013 , 8, e66953	3.7	18
392	Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. <i>PLoS ONE</i> , 2013 , 8, e81624	3.7	48
391	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. <i>PLoS ONE</i> , 2013 , 8, e53745	3.7	343
390	Statement on the Letters to the Editors by Starz and Bahmer. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012 , 10, 205-205	1.2	0
389	Melanoma cells in distinct growth phases retain specific invasive qualities during brain metastasis in vivo. <i>Pigment Cell and Melanoma Research</i> , 2012 , 25, 113-4	4.5	8
388	Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1087-99	5.4	21

387	Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 37-45	4.5	62
386	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. <i>European Journal of Cancer</i> , 2012 , 48, 2375-90	7.5	199
385	Recurrent nodules in a periauricular plaque-type blue nevus with fatal outcome. <i>Journal of Cutaneous Pathology</i> , 2012 , 39, 1088-93	1.7	22
384	Patterns of sun protection for young children: do we deliver the right sun-protection messages?. <i>British Journal of Dermatology</i> , 2012 , 166, 710	4	1
383	Ipilimumab with fotemustine in metastatic melanoma. <i>Lancet Oncology</i> , 2012 , 13, 851-2	21.7	2
382	Prognosis of sentinel node staged patients with primary cutaneous melanoma. <i>PLoS ONE</i> , 2012 , 7, e29793	3.7	12
381	Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells. <i>International Journal of Cancer</i> , 2012 , 131, 2165-74	7.5	8
380	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2012 , 367, 107-14	59.2	1634
379	Sekundärprävention von Hauttumoren nach Organtransplantation. <i>Onkologe</i> , 2012 , 18, 254-259	0.1	
378	Sekundärprävention von Hauttumoren. <i>Onkologe</i> , 2012 , 18, 237-242	0.1	
377	Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 48-53	4.6	35
376	Isotopic response of graft versus host disease following herpes zoster infection: case report and review of the literature. <i>Acta Dermato-Venereologica</i> , 2012 , 92, 383-4	2.2	9
375	Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. <i>British Journal of Cancer</i> , 2012 , 107, 422-8	8.7	102
374	CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 299-303	4.3	16
373	Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1835-41	2.2	99
372	Expression of oxytocin and its receptor in healthy and varicose great saphenous veins. <i>Pathology</i> , 2012 , 44, 670-3	1.6	4
371	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8502-8502	2.2	65
370	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA8509-LBA8509	2.2	10

369	A novel role for relaxin-2 in the pathogenesis of primary varicosis. <i>PLoS ONE</i> , 2012 , 7, e39021	3.7	7
368	Rare Tumors of the Skin and Subcutaneous Tissues. <i>Pediatric Oncology</i> , 2012 , 455-482	0.5	
367	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>New England Journal of Medicine</i> , 2011 , 364, 2517-26	59.2	3396
366	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
365	The stepwise two-photon excited melanin fluorescence is a unique diagnostic tool for the detection of malignant transformation in melanocytes. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 438-45	4.5	41
364	Histopathologische Befundung maligner Melanome in Bereinstimmung mit der AJCC-Klassifikation 2009: Literaturübersicht und Empfehlungen zum praktischen Vorgehen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 690-700	1.2	2
363	ECatenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. <i>PLoS ONE</i> , 2011 , 6, e23429	3.7	89
362	Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients. <i>Melanoma Research</i> , 2011 , 21, 244-52	3.3	29
361	Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. <i>Melanoma Research</i> , 2011 , 21, 228-34	3.3	25
360	Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. <i>International Journal of Dermatology</i> , 2011 , 50, 129-46	1.7	45
359	Extramammary Paget's disease: extended subclinical growth detected using three-dimensional histology in routine paraffin procedure and course of the disease. <i>Dermatologic Surgery</i> , 2011 , 37, 1417-26	1.7	18
358	Absence of merkel cell polyoma virus in cutaneous melanoma. <i>Experimental Dermatology</i> , 2011 , 20, 78-94		7
357	No evidence of viral genomes in whole-transcriptome sequencing of three melanoma metastases. <i>Experimental Dermatology</i> , 2011 , 20, 766-8	4	4
356	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 195-203	1.2	18
355	Oncogenetics of melanoma: basis for molecular diagnostics and therapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 510-6	1.2	1
354	Onkogenetik des Melanoms: Grundlage für molekulare Diagnostik und Therapie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 510-517	1.2	4
353	Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 690-9	1.2	20
352	Melanocytic nevi. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 723-34	1.2	10

351	Melanozytfe Nii. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 723-736	1.2	12
350	Hepatic hemangioma and hemochromatosis misdiagnosed by MRI as metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 842-3	1.2	
349	Fehldiagnose von Lebermetastasen eines Melanoms durch MRT bei Leberhñagiomen und Hñochromatose. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 842-843	1.2	
348	In Reply: Sentinel Lymph Node Biopsy in Melanoma. <i>Annals of Surgical Oncology</i> , 2011 , 18, 598-599	3.1	2
347	Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 487-93	7.4	42
346	Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. <i>Cancer</i> , 2011 , 117, 1697-703	6.4	98
345	Systematic review of medical treatment in melanoma: current status and future prospects. <i>Oncologist</i> , 2011 , 16, 5-24	5.7	394
344	Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial. <i>Melanoma Research</i> , 2011 , 21, 516-23	3.3	21
343	Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. <i>Melanoma Research</i> , 2011 , 21, 475-82	3.3	48
342	The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 468-79	4.3	49
341	Sorafenib and pegylated interferon-ß2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. <i>Annals of Oncology</i> , 2011 , 22, 1667-1674	10.3	23
340	A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2011 , 17, 7732-42	12.9	116
339	Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 8531-8531	2.2	4
338	Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. <i>PLoS ONE</i> , 2011 , 6, e16882	3.7	17
337	Non-AIDS associated Kaposi's sarcoma: clinical features and treatment outcome. <i>PLoS ONE</i> , 2011 , 6, e18397	3.7	36
336	Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 258-63	4.6	23
335	Diagnosis of cutaneous tumors with in vivo confocal laser scanning microscopy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010 , 8, 400-10	1.2	11
334	Determinants of survival in patients with brain metastases from cutaneous melanoma. <i>British Journal of Cancer</i> , 2010 , 102, 1213-8	8.7	130

333	Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. <i>Cancer Research</i> , 2010 , 70, 6999-7009	10.1	64
332	Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 841-6	2.2	65
331	Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1780-7	2.2	52
330	P35 Status quo of the S3 guideline Diagnosis, treatment and follow-up of melanoma in Germany. <i>Melanoma Research</i> , 2010 , 20, e58-e59	3.3	2
329	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2010 , 46, 270-83	7.5	230
328	Melanoma staging: facts and controversies. <i>Clinics in Dermatology</i> , 2010 , 28, 275-80	3	18
327	Incisional biopsy and melanoma prognosis: Facts and controversies. <i>Clinics in Dermatology</i> , 2010 , 28, 316-8	3	64
326	Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. <i>Clinics in Dermatology</i> , 2010 , 28, 311-5	3	16
325	Meeting report from the Third Global Workshop on Melanoma. <i>Pigment Cell and Melanoma Research</i> , 2010 , 23, e1-7	4.5	5
324	Genetic and morphologic features for melanoma classification. <i>Pigment Cell and Melanoma Research</i> , 2010 , 23, 763-70	4.5	116
323	Professional risk for skin cancer development in male mountain guides--a cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 797-804	4.6	35
322	P26b Outcome of sentinel node negative patients with primary cutaneous melanoma-prognostic factors and survival probabilities. <i>Melanoma Research</i> , 2010 , 20, e54-e55	3.3	4
321	Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. <i>Melanoma Research</i> , 2010 , 20, 163-70	3.3	55
320	Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. <i>Annals of Surgical Oncology</i> , 2010 , 17, 129-37	3.1	38
319	Systemische Therapie des metastasierten Melanoms. <i>Onkologe</i> , 2010 , 16, 1160-1166	0.1	1
318	Nachsorge des Melanoms [neue Aspekte. <i>Onkologe</i> , 2010 , 16, 1175-1181	0.1	
317	High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. <i>Cancer</i> , 2010 , 116, 4139-46	6.4	99
316	Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. <i>Melanoma Research</i> , 2010 , 20, 240-6	3.3	39

315 Malignes Melanom des Viszerum (Primärtumor und Metastasen) **2010**, 753-772

314 Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. *Journal of Clinical Oncology*, **2009**, 27, 2823-30 2.2 456

313 Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. *Journal of Clinical Oncology*, **2009**, 27, 3496-502 2.2 29

312 Nachsorge des malignen Melanoms. *Onkologe*, **2009**, 15, 777-783 0.1 0

311 Früherkennung und Prävention des malignen Melanoms. *Onkologe*, **2009**, 15, 738-743 0.1

310 Isolation of three stem cell lines from human sacrococcygeal teratomas. *Journal of Pathology*, **2009**, 217, 589-96 9.4 11

309 Clinical course and prognostic factors of Merkel cell carcinoma of the skin. *British Journal of Dermatology*, **2009**, 161, 90-4 4 32

308 Inflammatory nodules around the axilla: an uncommon localization of orf virus infection. *Clinical and Experimental Dermatology*, **2009**, 34, 240-2 1.8 9

307 Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. *Journal of Investigative Dermatology*, **2009**, 129, 1500-15 4.3 96

306 Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. *British Journal of Cancer*, **2009**, 101, 813-5 8.7 122

305 Melanoma epidemiology and trends. *Clinics in Dermatology*, **2009**, 27, 3-9 3 482

304 Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. *Journal of the American Academy of Dermatology*, **2009**, 60, 863-8 4.5 18

303 Dipeptidyl peptidase II is not a marker for progression in melanoma. *Journal of Dermatological Science*, **2009**, 53, 68-71 4.3 2

302 Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. *Pigment Cell and Melanoma Research*, **2009**, 22, 532-43 4.5 2

301 Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. *Journal of Immunotherapy*, **2009**, 32, 498-507 5 219

300 Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. *Melanoma Research*, **2009**, 19, 50-7 3.3 44

299 Cutaneous Metastases of Melanoma: New Treatment Options **2009**, 591-598

298 Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. *Journal of Investigative Dermatology*, **2008**, 128, 2013-23 4.3 107

297	Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 624, 89-103	3.6	464
296	Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. <i>Annals of Oncology</i> , 2008 , 19, 1195-201	10.3	99
295	Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. <i>Melanoma Research</i> , 2008 , 18, 61-7	3.3	74
294	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. <i>Oncologist</i> , 2008 , 13, 1001-11	5.7	273
293	Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). <i>Annals of Oncology</i> , 2008 , 19, 801-6	10.3	21
292	Aktuelle Therapie des malignen Melanoms. <i>Aktuelle Dermatologie</i> , 2008 , 34, 465-471	0.1	
291	Management of primary and metastasized melanoma in Germany in the time period 1976-2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Melanoma Research</i> , 2008 , 18, 112-9	3.3	4
290	Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. <i>Journal of Immunotherapy</i> , 2008 , 31, 180-8	5	166
289	Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. <i>Melanoma Research</i> , 2008 , 18, 353-8	3.3	18
288	Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. <i>Melanoma Research</i> , 2008 , 18, 152-60	3.3	50
287	Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. <i>Melanoma Research</i> , 2008 , 18, 274-8	3.3	71
286	Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. <i>American Journal of Dermatopathology</i> , 2008 , 30, 207-15	0.9	93
285	Improving melanoma classification by integrating genetic and morphologic features. <i>PLoS Medicine</i> , 2008 , 5, e120	11.6	264
284	Plasmid DNA- and messenger RNA-based anti-cancer vaccination. <i>Immunology Letters</i> , 2008 , 115, 33-42	4.1	76
283	Früherkennung und Primärprävention von Hautkrebs. <i>Onkologe</i> , 2008 , 14, 156-163	0.1	4
282	Age and gender are significant independent predictors of survival in primary cutaneous melanoma. <i>Cancer</i> , 2008 , 112, 1795-804	6.4	176
281	Noggin blocks invasive growth of murine B16-F1 melanoma cells in the optic cup of the chick embryo. <i>International Journal of Cancer</i> , 2008 , 122, 526-33	7.5	17
280	Distribution of muscarinic receptor subtype M3 in melanomas and their metastases. <i>Journal of Cutaneous Pathology</i> , 2008 , 35, 809-15	1.7	14

279	Short German guidelines: squamous cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008 , 6 Suppl 1, S5-8	1.2	35
278	Short German guidelines: Merkel cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008 , 6 Suppl 1, S15-6	1.2	36
277	Short German guidelines: basal cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008 , 6 Suppl 1, S2-4	1.2	29
276	Short German guidelines: dermatofibrosarcoma protuberans. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008 , 6 Suppl 1, S17-8	1.2	23
275	Short German guidelines: malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008 , 6 Suppl 1, S9-S14	1.2	68
274	Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, LBA9011-LBA9011	2.2	88
273	Treatment of melanoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2008 , 105, 845-51	2.5	11
272	The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. <i>International Journal of Cancer</i> , 2007 , 120, 2110-8	7.5	79
271	Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed?. <i>Cancer</i> , 2007 , 109, 1174-82	6.4	36
270	The mitochondrial DNA common deletion is present in most basal and squamous cell carcinoma samples isolated by laser capture microdissection but generally at reduced rather than increased levels. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 486-90	4.3	14
269	Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. <i>British Journal of Dermatology</i> , 2007 , 156, 1204-13	4	101
268	Kutanes Melanom. <i>Onkologe</i> , 2007 , 13, 745-758	0.1	
267	Neural crest cell migration of mouse B16-F1 melanoma cells transplanted into the chick embryo is inhibited by the BMP-antagonist noggin 2007 ,		4
266	Diagnosis and treatment of cutaneous melanoma: state of the art 2006. <i>Melanoma Research</i> , 2007 , 17, 117-27	3.3	157
265	Evidence and interdisciplinary consensus-based German guidelines: diagnosis and surveillance of melanoma. <i>Melanoma Research</i> , 2007 , 17, 393-9	3.3	98
264	Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. <i>European Journal of Cancer</i> , 2007 , 43, 557-64	7.5	150
263	A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2007 , 57, 616-21	4.5	63
262	New promises in the adjuvant, and palliative treatment of melanoma. <i>Cancer Treatment and Research</i> , 2007 , 135, 277-92	3.5	1

261	Neural crest cell migration of mouse B16-F1 melanoma cells transplanted into the chick embryo is inhibited by the BMP-antagonist noggin. <i>International Journal of Oncology</i> , 2007 , 31, 1367-78	1	10
260	The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. <i>Cancer</i> , 2006 , 107, 1331-9	6.4	96
259	The adhesion molecule L1 (CD171) promotes melanoma progression. <i>International Journal of Cancer</i> , 2006 , 119, 549-55	7.5	79
258	Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. <i>Annals of Oncology</i> , 2006 , 17, 1592-7	10.3	40
257	Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L. <i>Journal of Biological Chemistry</i> , 2006 , 281, 5406-15	5.4	73
256	Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2608-20	5.9	89
255	Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1188-94	2.2	63
254	Malignant melanoma: classification and staging of malignant melanoma. <i>Frontiers of Radiation Therapy and Oncology</i> , 2006 , 39, 149-158		3
253	Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. <i>European Journal of Cancer</i> , 2006 , 42, 342-50	7.5	85
252	The PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin sensitize melanoma cells to cisplatin and temozolomide. <i>Melanoma Research</i> , 2006 , 16, S94	3.3	2
251	Melanoma of the ear: prognostic factors and surgical strategies. <i>British Journal of Dermatology</i> , 2006 , 154, 310-8	4	35
250	Conventional histology vs. three-dimensional histology in lentigo maligna melanoma. <i>British Journal of Dermatology</i> , 2006 , 154, 453-9	4	50
249	Comparative analysis of incidence and clinical features of cutaneous malignant melanoma in Crete (Greece) and southern Germany (central Baden-Württemberg). <i>British Journal of Dermatology</i> , 2006 , 154, 1123-7	4	11
248	Basal cell carcinoma: histological classification and body-site distribution. <i>British Journal of Dermatology</i> , 2006 , 155, 401-7	4	129
247	Correlation with digital dermoscopic images can help dermatopathologists to diagnose equivocal skin tumours. <i>British Journal of Dermatology</i> , 2006 , 155, 546-51	4	19
246	Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. <i>British Journal of Dermatology</i> , 2006 , 155, 771-7	4	82
245	Generation of multiple stable dermcidin-derived antimicrobial peptides in sweat of different body sites. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 354-65	4.3	59
244	Melanoma of the nose: prognostic factors, three-dimensional histology, and surgical strategies. <i>Laryngoscope</i> , 2006 , 116, 1204-11	3.6	11

243	A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 8044-8044	2.2	14
242	Histopathologie des Melanoms 2006 , 139-156		
241	Kosten und Nutzen der Ausbreitungsdiagnostik beim Melanom 2006 , 171-179		
240	Adjuvante medikamentöse Therapie des Melanoms 2006 , 275-283		1
239	Epidemiologie des Melanoms der Haut 2006 , 49-62		
238	Malignes Melanom des Viszerum (Primärtumor und Metastasen) 2006 , 733-750		
237	Melanozytäre Nävi und maligne Melanome 2006 , 121-143		
236	Merkel-Zell-Tumor 2006 , 5148-5156		
235	Imiquimod in the treatment of extensive recurrent lentigo maligna. <i>Journal of the American Academy of Dermatology</i> , 2005 , 52, 51-2	4.5	32
234	Cutaneous melanoma: baseline and ongoing laboratory evaluation. <i>Dermatologic Therapy</i> , 2005 , 18, 413-21		8
233	Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy. <i>British Journal of Dermatology</i> , 2005 , 152, 87-92	4	87
232	Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas. <i>British Journal of Dermatology</i> , 2005 , 153, 1159-65		13
231	Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children. <i>International Journal of Cancer</i> , 2005 , 115, 121-6	7.5	67
230	Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior. <i>International Journal of Cancer</i> , 2005 , 116, 755-61	7.5	43
229	Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Cancer</i> , 2005 , 103, 616-24	6.4	79
228	Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. <i>Genetic Vaccines and Therapy</i> , 2005 , 3, 6		24
227	Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9001-7	2.2	95
226	Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. <i>Journal of Immunology</i> , 2005 , 174, 8003-10	5.3	208

225	Effect of sunscreen and clothing on the number of melanocytic nevi in 1,812 German children attending day care. <i>American Journal of Epidemiology</i> , 2005 , 161, 620-7	3.8	66
224	Variability of dermoscopic features of tungiasis. <i>Archives of Dermatology</i> , 2005 , 141, 643-4		22
223	Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005 , 43, 557-63	5.9	22
222	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. <i>Frontiers in Bioscience - Landmark</i> , 2005 , 10, 2986-3001	2.8	208
221	Sonnenschutz: Was ist zuviel, was ist zuwenig?. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2005 , 504-511		
220	Dermatoskopie. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2005 , 611-623		
219	Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren 2005 ,		5
218	Is sentinel lymph node biopsy of therapeutic relevance for melanoma?. <i>Dermatology</i> , 2004 , 209, 5-13	4.4	18
217	Psychosoziale Belastung und subjektives Erleben von Melanompatienten in der ambulanten Nachsorge. <i>Aktuelle Dermatologie</i> , 2004 , 30, 149-157	0.1	3
216	Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3660-7	2.2	88
215	Blue light phototherapy of neonatal jaundice does not increase the risk for melanocytic nevus development. <i>Archives of Dermatology</i> , 2004 , 140, 493-4		20
214	Dermoscopy of tungiasis. <i>Archives of Dermatology</i> , 2004 , 140, 761-3		43
213	Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4376-83	2.2	36
212	Risk estimation for malignant transformation of melanocytic nevi. <i>Archives of Dermatology</i> , 2004 , 140, 127; author reply 127		13
211	Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma?. <i>Dermatology</i> , 2004 , 209, 249-50	4.4	14
210	Clinical risk factors and prognostic significance of local recurrence in cutaneous melanoma. <i>British Journal of Dermatology</i> , 2004 , 151, 397-406	4	40
209	Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. <i>British Journal of Dermatology</i> , 2004 , 151, 534-9	4	99
208	Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions. <i>British Journal of Dermatology</i> , 2004 , 151, 1029-38	4	113

207	Micrometastasis of a sentinel lymph node in cutaneous melanoma is a significant prognostic factor for disease-free survival, distant-metastasis-free survival, and overall survival. <i>Dermatologic Surgery</i> , 2004 , 30, 1319-28	1.7	19
206	Value of the clinical history for different users of dermoscopy compared with results of digital image analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004 , 18, 665-9	4.6	45
205	Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. <i>Journal of Investigative Dermatology</i> , 2004 , 122, 1293-301	4.3	51
204	Adjuvante medikamentöse Therapie des malignen Melanoms. <i>Onkologe</i> , 2004 , 10, 710	0.1	0
203	Epidemiologie und Risikofaktoren des malignen Melanoms. <i>Onkologe</i> , 2004 , 10, 688	0.1	1
202	Strahlentherapie des Melanoms. <i>Onkologe</i> , 2004 , 10, 717	0.1	1
201	Risikoadaptierte Nachsorge des malignen Melanoms. <i>Onkologe</i> , 2004 , 10, 745	0.1	0
200	Dermatofibrosarcoma protuberans--an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2004 , 2, 661-7	1.2	6
199	Additional reverse transcription-polymerase chain reaction of peripheral slices is not superior to analysis of the central slice in sentinel lymph nodes from melanoma patients. <i>British Journal of Dermatology</i> , 2004 , 150, 477-83	4	6
198	The natural course of cutaneous melanoma. <i>Journal of Surgical Oncology</i> , 2004 , 86, 172-8	2.8	179
197	Malignant blue naevus of the scalp. <i>Lancet Oncology, The</i> , 2004 , 5, 429	21.7	
196	Micrometastasis of a Sentinel Lymph Node in Cutaneous Melanoma Is a Significant Prognostic Factor for Disease-Free Survival, Distant-Metastasis-Free Survival, and Overall Survival. <i>Dermatologic Surgery</i> , 2004 , 30, 1319-1328	1.7	11
195	Functional Surgery in Subungual Melanoma. <i>Dermatologic Surgery</i> , 2003 , 29, 366-374	1.7	63
194	Surveillance and follow-up examinations in cutaneous melanoma. <i>Oncology Research and Treatment</i> , 2003 , 26, 241-6	2.8	16
193	Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood: a risk factor study in 1,812 kindergarten children. <i>Cancer</i> , 2003 , 97, 628-38	6.4	108
192	Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. <i>Cancer</i> , 2003 , 97, 1737-45	6.4	97
191	Continuous long-term monitoring of UV radiation in professional mountain guides reveals extremely high exposure. <i>International Journal of Cancer</i> , 2003 , 103, 775-8	7.5	67
190	Exclusion of BRAFV599E as a melanoma susceptibility mutation. <i>International Journal of Cancer</i> , 2003 , 106, 78-80	7.5	32

189	Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma. <i>Experimental Dermatology</i> , 2003 , 12, 296-306	4	35
188	Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. <i>Pigment Cell & Melanoma Research</i> , 2003 , 16, 297-306		136
187	Direct effects on proliferation, antigen expression and melanin synthesis of cultured normal human melanocytes in response to UVB and UVA light. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2003 , 19, 122-7	2.4	18
186	"Functional" surgery in subungual melanoma. <i>Dermatologic Surgery</i> , 2003 , 29, 366-74	1.7	102
185	The dermoscopic classification of atypical melanocytic naevi (Clark naevi) is useful to discriminate benign from malignant melanocytic lesions. <i>British Journal of Dermatology</i> , 2003 , 149, 1159-64	4	44
184	Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. <i>British Journal of Cancer</i> , 2003 , 89, 1620-6	8.7	145
183	Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. <i>American Journal of Pathology</i> , 2003 , 162, 1951-60	5.8	420
182	Modified ABC-point list of dermoscopy: A simplified and highly accurate dermoscopic algorithm for the diagnosis of cutaneous melanocytic lesions. <i>Journal of the American Academy of Dermatology</i> , 2003 , 48, 672-8	4.5	76
181	Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. <i>Lancet Oncology</i> , 2003 , 4, 748-59	21.7	247
180	Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 520-9	2.2	206
179	Polymorphisms of the BRAF gene predispose males to malignant melanoma. <i>Journal of Carcinogenesis</i> , 2003 , 2, 7	1.9	30
178	Melanozytäre Nävi und malignes Melanom 2003 , 593-649		4
177	The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. <i>Cancer Research</i> , 2003 , 63, 7515-9	10.1	142
176	Detection of dermcidin-derived peptides in sweat by ProteinChip technology. <i>Journal of Immunological Methods</i> , 2002 , 270, 53-62	2.5	43
175	The New American Joint Committee on Cancer staging system for cutaneous melanoma: a critical analysis based on data of the German Central Malignant Melanoma Registry. <i>Cancer</i> , 2002 , 94, 2305-7	6.4	15
174	Früherkennung von Hautkrebs. <i>Onkologe</i> , 2002 , 8, 1064-1071	0.1	
173	Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. <i>Journal of Investigative Dermatology</i> , 2002 , 119, 1090-5	4.3	213
172	Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. <i>British Journal of Dermatology</i> , 2002 , 147, 62-70	4	230

171	Molecular diagnostics facilitate distinction between lethal and non-lethal subtypes of junctional epidermolysis bullosa: a case report and review of the literature. <i>European Journal of Pediatrics</i> , 2002 , 161, 672-9	4.1	12
170	Der Kenntnisstand der Dermatologen in Praxis und Klinik zum Melanom. <i>Aktuelle Dermatologie</i> , 2002 , 28, 456-458	0.1	
169	Fine needle aspiration in the diagnosis of metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 147-8	4.5	2
168	Dermoscopic classification of Clark's nevi (atypical melanocytic nevi). <i>Clinics in Dermatology</i> , 2002 , 20, 255-8	3	20
167	Pseudolymphome, PrLymphome und Lymphome der Haut 2002 , 1075-1112		
166	Lichtdermatosen und Lichtschutz 2002 , 793-813		
165	Epitheliale Präkanzerosen und Karzinome der Haut 2002 , 861-893		
164	Sklerodermie und sklerodermiforme Dermatosen 2002 , 549-575		
163	Kutane Borreliosen 2002 , 103-115		
162	HIV-Infektion und Kaposi-Sarkom 2002 , 1015-1074		1
161	Sonstige Hauttumoren 2002 , 969-983		
160	Lupus erythematoses und verwandte Immunopathien einschließlich Überlappungssyndromen 2002 , 513-535		
159	Malignes Melanom 2002 , 931-967		
158	Melanozytäre Nävi und Melanomvorläufer 2002 , 895-929		0
157	A rational approach to the follow-up of melanoma patients. <i>Recent Results in Cancer Research</i> , 2002 , 160, 205-15	1.5	20
156	Nodular scabies detected by computed dermatoscopy. <i>Dermatology</i> , 2001 , 203, 190-1	4.4	26
155	The dermatoscopic pattern of clear-cell acanthoma resembles psoriasis vulgaris. <i>Dermatology</i> , 2001 , 203, 50-2	4.4	50
154	Hyperkeratosis lenticularis perstans (Flegel's disease)--lack of response to treatment with tacalcitol and calcipotriol. <i>Dermatology</i> , 2001 , 202, 255-8	4.4	12

153	Epidemiologie, Prävention und Nachsorge maligner Melanome. <i>Onkologe</i> , 2001 , 7, 18-35	0.1	1
152	Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas?. <i>British Journal of Dermatology</i> , 2001 , 144, 66-70	4	31
151	Intralesional rituximab for cutaneous B-cell lymphoma. <i>British Journal of Dermatology</i> , 2001 , 144, 1239-43	4	61
150	Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. <i>British Journal of Dermatology</i> , 2001 , 145, 195-202	4	42
149	Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. <i>Journal of Investigative Dermatology</i> , 2001 , 116, 319-29	4.3	93
148	HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. <i>Journal of Investigative Dermatology</i> , 2001 , 116, 891-7	4.3	119
147	Differenzialdiagnose pigmentierter Hautveränderungen und Melanombehandlung am unteren Genitaltrakt der Frau. <i>Der Gynäkologe</i> , 2001 , 34, 634-640	0.1	1
146	Dermcidin: a novel human antibiotic peptide secreted by sweat glands. <i>Nature Immunology</i> , 2001 , 2, 1133-7	9.1	513
145	Dermoscopic classification of atypical melanocytic nevi (Clark nevi). <i>Archives of Dermatology</i> , 2001 , 137, 1575-80		93
144	Does intensive histopathological workup by serial sectioning increase the detection of lymph node micrometastasis in patients with primary cutaneous melanoma?. <i>Melanoma Research</i> , 2001 , 11, 57-63	3.3	15
143	Dermatoscopy turns histopathologist's attention to the suspicious area in melanocytic lesions. <i>Archives of Dermatology</i> , 2001 , 137, 1338-40		45
142	Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). <i>British Journal of Cancer</i> , 2001 , 84, 1036-42	8.7	67
141	Epidemiology of cutaneous melanoma in Germany and worldwide. <i>Skin Pharmacology and Physiology</i> , 2001 , 14, 280-90	3	114
140	Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1723-7	2.2	36
139	Familiales Melanom 2001 , 43-55		
138	Melanomnachsorge: Welche Untersuchungen sind sinnvoll?. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2001 , 307-313		
137	Malignes Melanom des Viszerum (Primärtumor und Metastasen) 2001 , 755-771		
136	Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma. <i>Recent Results in Cancer Research</i> , 2001 , 158, 137-46	1.5	17

135	Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients. <i>Recent Results in Cancer Research</i> , 2001 , 158, 93-104	1.5	16
134	Extreme UV exposure of professional cyclists. <i>Dermatology</i> , 2000 , 201, 44-5	4.4	62
133	Personal UV dosimetry by Bacillus subtilis spore films. <i>Dermatology</i> , 2000 , 200, 1-5	4.4	40
132	Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?. <i>Melanoma Research</i> , 2000 , 10, 451-9	3.3	42
131	Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients. <i>Cancer</i> , 2000 , 88, 2534-9	6.4	144
130	Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. <i>Cancer</i> , 2000 , 89, 1260-78	4.3	132
129	Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , 2000 , 114, 637-42	4.3	136
128	Is morphoea caused by Borrelia burgdorferi? A review. <i>British Journal of Dermatology</i> , 2000 , 142, 636-44	4	78
127	Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. <i>British Journal of Dermatology</i> , 2000 , 143, 275-80	4	372
126	Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction. <i>British Journal of Dermatology</i> , 2000 , 143, 780-5	4	42
125	Melanocytes in nevi and melanomas synthesize basement membrane and basement membrane-like material. An immunohistochemical and electron microscopic study including immunoelectron microscopy. <i>Journal of Cutaneous Pathology</i> , 2000 , 27, 67-75	1.7	20
124	Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization. <i>British Journal of Cancer</i> , 2000 , 82, 1149-57	8.7	20
123	Differenzialdiagnose pigmentierter Hautveränderungen und Melanombehandlung am unteren Genitaltrakt der Frau. <i>Onkologie</i> , 2000 , 6, 1083-1090	0.1	3
122	Bacillus subtilis spore film dosimeters in personal dosimetry for occupational solar ultraviolet exposure. <i>International Archives of Occupational and Environmental Health</i> , 2000 , 73, 575-80	3.2	39
121	High prevalence of seborrhoeic dermatitis on the face and scalp in mountain guides. <i>Dermatology</i> , 2000 , 201, 146-7	4.4	39
120	Solar UV-protective properties of textiles. <i>Dermatology</i> , 2000 , 201, 82	4.4	17
119	Agreement between self-assessment of melanocytic nevi by patients and dermatologic examination. <i>American Journal of Epidemiology</i> , 2000 , 151, 72-7	3.8	46
118	Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. <i>Melanoma Research</i> , 2000 , 10, 165-169	3.3	100

117	Predictors of the use of sunscreen in dermatological patients in Central Europe. <i>Preventive Medicine</i> , 2000 , 31, 134-9	4.3	23
116	Human melanoma progression in skin reconstructs : biological significance of bFGF. <i>American Journal of Pathology</i> , 2000 , 156, 193-200	5.8	177
115	Molekulare Diagnose des malignen Melanoms 2000 , 482-485		
114	Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. <i>British Journal of Dermatology</i> , 1999 , 141, 30-6	4	79
113	Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription-polymerase chain reaction. <i>British Journal of Dermatology</i> , 1999 , 141, 37-43	4	37
112	Awareness and early detection of cutaneous melanoma: an analysis of factors related to delay in treatment. <i>British Journal of Dermatology</i> , 1999 , 141, 783-7	4	66
111	Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines. <i>International Journal of Cancer</i> , 1999 , 82, 583-6	7.5	16
110	Does mountaineering increase the incidence of cutaneous melanoma? A hypothesis based on cancer registry data. <i>Dermatology</i> , 1999 , 199, 201-3	4.4	17
109	Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. <i>American Journal of Surgical Pathology</i> , 1999 , 23, 822-8	6.7	80
108	Die Entwicklung der Ultraschalldiagnostik in der Dermatologie 1999 , 1-7		
107	Die Prävention des Malignen Melanoms: Beispiele aus Australien und Deutschland. <i>Fortschritte Der Operativen Dermatologie</i> , 1999 , 25-34		
106	Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. <i>International Journal of Cancer</i> , 1998 , 79, 318-23	7.5	63
105	Adjuvante Interferon- α -Therapie beim Melanom. <i>Onkologe</i> , 1998 , 4, 256-259	0.1	
104	Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. <i>Journal of Investigative Dermatology</i> , 1998 , 110, 752-5	4.3	141
103	Treatment of psoriasis with interleukin-10. <i>Journal of Investigative Dermatology</i> , 1998 , 111, 1235-6	4.3	41
102	RNA isolation from human skin tissues for colorimetric differential display. <i>Journal of Proteomics</i> , 1998 , 37, 131-5		15
101	Application of argon plasma coagulation in skin surgery. <i>Dermatology</i> , 1998 , 197, 152-7	4.4	24
100	Molecular events in melanoma development and progression. <i>Frontiers in Bioscience - Landmark</i> , 1998 , 3, D1005-10	2.8	96

99	Leitlinien und Qualitätssicherung für Diagnose und Therapie des malignen Melanoms 1998 , 254-261		2
98	Malignes Melanom 1998 , 799-829		4
97	Lymphknotenultraschall führt zur Erstentdeckung von regionalen Metastasen bei einem Drittel der Patienten mit Melanom 1998 , 262-264		
96	Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. <i>Melanoma Research</i> , 1997 , 7, 197-208	3:3	30
95	Inactivation of ribonucleotide reductase in tumour cells and inhibition of tumour cell growth by p-alkoxyphenols. <i>Melanoma Research</i> , 1997 , 7, 288-98	3:3	7
94	Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. <i>Journal of Clinical Epidemiology</i> , 1997 , 50, 1201-10	5:7	36
93	Seasonal patterns in the diagnosis of cutaneous malignant melanoma: analysis of the data of the German Central Malignant Melanoma Registry. <i>British Journal of Dermatology</i> , 1997 , 136, 968-9	4	14
92	Prolonged survival of 2 years or longer for patients with disseminated melanoma. <i>Cancer</i> , 1997 , 79, 2345-53	6:3	117
91	Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. <i>Cancer</i> , 1997 , 80, 60-5	6:4	107
90	Melanozytäre Nävi und Melanomrisiko: Leitlinien für die Betreuung und Therapie 1997 , 215-230		5
89	Klinik und Histologie des malignen Melanoms 1997 , 247-270		5
88	Epidemiologie des Hautkrebses 1997 , 40-56		11
87	Seasonal Patterns in the Diagnosis of Cutaneous Malignant Melanoma due to Differential Detection Rather than Biological Causes. An Analysis of the Data of the German Central Malignant Melanoma Registry 1997 , 519-526		
86	Prävention des malignen Melanoms – Strategien, Ergebnisse und Perspektiven in verschiedenen Ländern 1997 , 414-424		
85	Recent Epidemiological Trends of Cutaneous Melanoma in Germany, Austria and Switzerland. Results of the Central Malignant Melanoma Registry 1997 , 507-518		
84	Nachsorge bei Melanompatienten 1997 , 407-413		1
83	Prolonged survival of 2 years or longer for patients with disseminated melanoma 1997 , 79, 2345		4
82	Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. <i>Cancer</i> , 1997 , 79, 2345-53	6:4	20

81	Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma. A case-control study of the German Central Malignant Melanoma Registry. <i>Acta Dermato-Venereologica</i> , 1997 , 77, 374-8	2.2	8
80	Failure of gadopentetate dimeglumine-enhanced, high-resolution magnetic resonance imaging to differentiate among melanin-containing skin tumors. <i>Academic Radiology</i> , 1996 , 3, 186-91	4.3	6
79	Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile?. <i>European Journal of Cancer</i> , 1996 , 32, 1635-1638	7.5	
78	Oral hairy leukoplakia in 71 HIV-seropositive patients: clinical symptoms, relation to immunologic status, and prognostic significance. <i>Journal of the American Academy of Dermatology</i> , 1996 , 35, 928-34	4.5	33
77	K ⁺ channels and the intracellular calcium signal in human melanoma cell proliferation. <i>Journal of Membrane Biology</i> , 1996 , 151, 149-57	2.3	70
76	Persistent scleredema of Buschke in a diabetic: improvement with high-dose penicillin. <i>British Journal of Dermatology</i> , 1996 , 134, 597-598	4	15
75	Primäre Diagnose, Ausbreitungsdiagnostik und Prognoseschätzung des malignen Melanoms. <i>Onkologe</i> , 1996 , 2, 441-448	0.1	9
74	Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. <i>Archives of Dermatology</i> , 1996 , 132, 1473-8		13
73	Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. <i>Archives of Dermatological Research</i> , 1995 , 287, 259-63	3.3	22
72	Identification of genes specifically regulated in human melanoma cells. <i>Archives of Dermatological Research</i> , 1995 , 287, 421-7	3.3	9
71	Cutaneous metastatic angiosarcoma with a lethal outcome, following radiotherapy for a cervical carcinoma. <i>British Journal of Dermatology</i> , 1995 , 133, 610-4	4	22
70	Incomplete expression of the tyrosinase gene family (tyrosinase, TRP-1, and TRP-2) in human malignant melanoma cells in vitro. <i>Pigment Cell & Melanoma Research</i> , 1995 , 8, 307-13		33
69	Prothymosin alpha 1 modulates lymphokine-activated killer cell activity and IL-2 production by peripheral blood lymphocytes from melanoma patients in vitro. <i>International Journal of Immunopharmacology</i> , 1995 , 17, 555-61		11
68	Synergistic interactions between interferon beta and carboplatin on SK-MEL 28 human melanoma cell growth inhibition in vitro. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121, 84-8	4.9	2
67	Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis. <i>Melanoma Research</i> , 1995 , 5, 189-94	3.3	28
66	Role of high-resolution magnetic resonance imaging for differentiating melanin-containing skin tumors. <i>Investigative Radiology</i> , 1995 , 30, 638-43	10.1	24
65	Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. <i>Cancer</i> , 1995 , 75, 2484-91	6.4	189
64	Primary cutaneous melanoma. Prognostic classification of anatomic location. <i>Cancer</i> , 1995 , 75, 2492-8	6.4	184

63	Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. <i>Cancer</i> , 1995 , 75, 2499-2506	6.4	144
62	Overall and site-specific risk of malignant melanoma associated with nevus counts at different body sites: a multicenter case-control study of the German Central Malignant-Melanoma Registry. <i>International Journal of Cancer</i> , 1995 , 62, 393-7	7.5	52
61	Production of cytokines by human melanoma cells and melanocytes. <i>Recent Results in Cancer Research</i> , 1995 , 139, 155-68	1.5	30
60	Growth control of melanoma cells and melanocytes by cytokines. <i>Recent Results in Cancer Research</i> , 1995 , 139, 169-82	1.5	67
59	Kaposi's Sarcoma: A Reevaluation. <i>Recent Results in Cancer Research</i> , 1995 , 275-296	1.5	19
58	Perspectives of cytokine treatment in malignant skin tumors. <i>Recent Results in Cancer Research</i> , 1995 , 139, 349-69	1.5	15
57	Photodynamic action of ultraviolet A: induction of cellular hydroperoxides. <i>Recent Results in Cancer Research</i> , 1995 , 139, 43-55	1.5	3
56	Protein patterns of benign and malignant human melanocytes show consistent changes in gene expression. <i>Recent Results in Cancer Research</i> , 1995 , 139, 123-35	1.5	7
55	Malignes Melanom 1995 , 674-702		3
54	HIV-Infektion und Kaposi-Sarkom 1995 , 937-986		
53	Zytokintherapien bei malignen Hauttumoren 1995 , 1021-1041		
52	Alterung und Altershaut 1995 , 1281-1303		
51	Pigmentzellen und Melanomvorläufer 1995 , 835-853		
50	Pseudolymphome, Prälymphome und Lymphome der Haut 1995 , 987-1020		1
49	Lichtdermatosen und Lichtschutz 1995 , 729-749		
48	Prognoseverbesserung durch Kontinuierliche Dissektion nach Lymphabstromszintigraphie bei Rumpfmelanomen. <i>Fortschritte Der Operativen Dermatologie</i> , 1995 , 251-258		2
47	Stellenwert der Zytokintherapie in der Dermatooonkologie. <i>Fortschritte Der Operativen Dermatologie</i> , 1995 , 251-257		
46	Kutane Borreliosen 1995 , 99-109		

45 Malignes Melanom **1995**, 855-889

44	The influence of the thymic preparation thymex-L on deficient antitumor-activity of monocytes from melanoma patients in-vitro. <i>Oncology Reports</i> , 1995 , 2, 469-72	3.5	3
43	Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Journal of Investigative Dermatology</i> , 1994 , 102, 700-5	4.3	120
42	P53 mutation and c-fos overexpression are associated with detection of the antigen VLA-2 in human melanoma cell lines. <i>Pigment Cell & Melanoma Research</i> , 1994 , 7, 348-53		17
41	Expression of interleukin 10 in human melanoma. <i>British Journal of Cancer</i> , 1994 , 70, 1182-5	8.7	120
40	Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Journal of Investigative Dermatology</i> , 1994 , 102, 695-9	4.3	203
39	Prothymosin alpha augments deficient antitumor activity of monocytes from melanoma patients in vitro. <i>Anticancer Research</i> , 1994 , 14, 2405-11	2.3	9
38	Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. <i>Anticancer Research</i> , 1994 , 14, 2565-71	2.3	29
37	Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis. <i>Seminars in Oncology</i> , 1994 , 21, 12-6	5.5	11
36	Effects of Interferons and Cytokines on Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 1993 , 100, S239-S244	4.3	20
35	Cytokines in human melanoma cells. <i>Melanoma Research</i> , 1993 , 3, 425-434	3.3	30
34	Identification of genes specifically regulated in melanoma cells. <i>Melanoma Research</i> , 1993 , 3, 72	3.3	6
33	12-O-tetradecanoylphorbol-13-acetate not only modulates proliferation rates, but also alters antigen expression and LAK-cell susceptibility of normal human melanocytes in vitro. <i>Journal of Investigative Dermatology</i> , 1993 , 100, 653-9	4.3	14
32	Effects of interferons and cytokines on melanoma cells. <i>Journal of Investigative Dermatology</i> , 1993 , 100, 239S-244S	4.3	12
31	Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. <i>Melanoma Research</i> , 1993 , 3, 291-9	3.3	43
30	Cytokines in human melanoma cells: synthesis, autocrine stimulation and regulatory functions--an overview. <i>Melanoma Research</i> , 1993 , 3, 425-33	3.3	8
29	Proliferation and morphology of melanoma cells and benign human melanocytes under varying culture conditions. <i>Melanoma Research</i> , 1993 , 3, 107-12	3.3	3
28	Effects of Interferons and Cytokines on Melanoma Cells.. <i>Journal of Investigative Dermatology</i> , 1993 , 100, 239S-244S	4.3	8

27	The German melanoma registry and environmental risk factors implied. <i>Recent Results in Cancer Research</i> , 1993 , 128, 69-89	1.5	22
26	Dysplastic nevi-dysplastic nevus syndromes: clinical features and genetic aspects. <i>Recent Results in Cancer Research</i> , 1993 , 128, 101-18	1.5	6
25	Malignes Melanom: Epidemiologie und Risikofaktoren. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 1993 , 149-154		
24	Malignes Melanom 1993 , 229-250		1
23	Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Pigment Cell & Melanoma Research</i> , 1992 , Suppl 2, 285-94		11
22	Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. Results of a case control study in melanoma patients and nonmelanoma control subjects. <i>Journal of the American Academy of Dermatology</i> , 1992 , 26, 920-6	4.5	83
21	A rapid and sensitive fluorometric microassay for determining cell mediated cytotoxicity to adherent growing cell lines. <i>Journal of Immunological Methods</i> , 1992 , 156, 1-8	2.5	19
20	4th ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR PIGMENT CELL RESEARCH Berlin, Germany, September 17-19, 1992. <i>Pigment Cell & Melanoma Research</i> , 1992 , 5, 168-168		2
19	The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. <i>British Journal of Cancer</i> , 1992 , 66, 856-61	8.7	78
18	Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. <i>Seminars in Oncology</i> , 1992 , 19, 63-9	5.5	2
17	A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro. <i>Melanoma Research</i> , 1991 , 1, 91-5	3.3	38
16	A case of classical mycosis fungoides associated with human T-cell lymphotropic virus type I. <i>British Journal of Dermatology</i> , 1991 , 124, 198-202	4	41
15	Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV-negative patient after prednisolone treatment. Spontaneous regression 8 months after discontinuing therapy. <i>International Journal of Dermatology</i> , 1991 , 30, 114-20	1.7	21
14	Disseminated malignant melanoma. New therapeutic approaches. <i>International Journal of Dermatology</i> , 1991 , 30, 239-42	1.7	4
13	Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. <i>Journal of Investigative Dermatology</i> , 1991 , 97, 364-72	4.3	41
12	Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. <i>Journal of the American Academy of Dermatology</i> , 1991 , 24, 584-90	4.5	193
11	Incidence and mortality of malignant melanoma in Berlin (West) from 1980 to 1986. <i>Acta Dermato-Venereologica</i> , 1991 , 71, 506-11	2.2	5
10	Epidemiologie des malignen Melanoms: Aktueller Stand in der Bundesrepublik Deutschland. <i>Verhandlungen Der Deutschen Dermatologischen Gesellschaft</i> , 1991 , 71-79		

9	Epidemiologie des malignen Melanoms 1991 , 1-14		1
8	Staphylococcus aureus in atopic dermatitis and in nonatopic dermatitis. <i>International Journal of Dermatology</i> , 1990 , 29, 579-82	1.7	31
7	Cytostatic and cytotoxic effects of recombinant tumor necrosis factor-alpha on sensitive human melanoma cells in vitro may result in selection of cells with enhanced markers of malignancy. <i>Journal of Investigative Dermatology</i> , 1990 , 95, 223S-230S	4.3	16
6	Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. <i>Journal of Investigative Dermatology</i> , 1990 , 95, 231S-237S	4.3	68
5	Change of Epidemiological Characteristics of Malignant Melanoma during the Years 1962-1972 and 1983-1986 in the Federal Republic of Germany. <i>Dermatology</i> , 1989 , 178, 131-135	4.4	27
4	Markers and relative risk in a German population for developing malignant melanoma. <i>International Journal of Dermatology</i> , 1989 , 28, 517-23	1.7	104
3	Interferons in dermatology. <i>Journal of the American Academy of Dermatology</i> , 1989 , 20, 650-6	4.5	55
2	Change of epidemiological characteristics of malignant melanoma during the years 1962-1972 and 1983-1986 in the Federal Republic of Germany. <i>Dermatologica</i> , 1989 , 178, 131-5		1
1	Malignes Melanom 898-917		